Invesco
AVTX icon

Invesco’s Avalo Therapeutics AVTX Stock Holding History

Invesco’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7
Closed -$14K – 4046
2022
Q1 		$14K Hold
7
– – ﹤0.01% 3996
2021
Q4 		$33K Hold
7
– – ﹤0.01% 4007
2021
Q3 		$41K Buy
7
+2
+40% +$16.2K ﹤0.01% 4006
2021
Q2 		$45K Sell
5
-4
-44% -$33.5K ﹤0.01% 3952
2021
Q1 		$76K Hold
9
– – ﹤0.01% 3793
2020
Q4 		$71K Sell
9
-5
-36% -$34.7K ﹤0.01% 3692
2020
Q3 		$90K Sell
14
-11
-44% -$82.7K ﹤0.01% 3578
2020
Q2 		$188K Buy
25
+4
+19% +$29K ﹤0.01% 3490
2020
Q1 		$149K Buy
21
+3
+17% +$31.7K ﹤0.01% 3483
2019
Q4 		$280K Sell
18
-1
-5% -$10.5K ﹤0.01% 3444
2019
Q3 		$177K Hold
19
– – ﹤0.01% 3569
2019
Q2 		$300K Sell
19
-13
-41% -$197K ﹤0.01% 3502
2019
Q1 		$540K Sell
32
-12
-27% -$180K ﹤0.01% 3282
2018
Q4 		$412K Sell
44
-6
-12% -$66.9K ﹤0.01% 3350
2018
Q3 		$668K Buy
50
+24
+92% +$315K ﹤0.01% 3312
2018
Q2 		$327K Buy
+26
New +$310K ﹤0.01% 3566

Other funds holding AVTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's AVTX Position: Q2 2022 in Review

Invesco sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 7 shares — an estimated $14K sold.

Invesco first reported a position in AVTX in Q2 2018 and held it in 16 quarters. The position peaked at $668K in Q3 2018. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • Invesco reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 7 Avalo Therapeutics shares in Q2 2022, an estimated $14K.
  • Invesco first reported a position in Avalo Therapeutics in Q2 2018 and held it in 16 quarters.
  • Invesco's Avalo Therapeutics position peaked at $668K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.